Peptide Cycling Protocols for Fat-Loss Stacks

Why Most Users Don't 'Blast and Cruise' Peptides

If you're coming from the world of anabolic steroids, most peptide guides say the 'blast and cruise' habit doesn't carry over. That habit means running high doses for a cycle, then dropping to a lower dose indefinitely. The reasoning in community guides is that peptides aren't blunt instruments. They act on very specific receptors on your cells, and constant stimulation can wear that response down.

Most of the peptides used for fat loss and body composition, particularly the growth hormone secretagogues (GHS), work by interacting with receptor systems that adapt. Your body is constantly trying to maintain balance, or homeostasis. When a receptor gets a signal around the clock, one predictable response is that the cell starts ignoring the signal.

Cells can pull receptors from the surface, making them less available. This is called receptor downregulation. Forum posts describe the result as the same dose that gave great results in week two doing little by week twelve. Cycling is the community's answer to that problem, though as of October 2026 no controlled human trial has tested whether it works for the common fat-loss stacks.

The Science of Burnout: Tachyphylaxis

This phenomenon has a name: tachyphylaxis. It's a rapid decrease in the response to a drug after repeated administration. It's the same idea as a cup of coffee not hitting as hard after a year of daily use, because the body adapts to caffeine.

With peptides, two receptor types matter for the classic fat-loss stacks:

1. GHRH Receptor: This is the target for peptides like CJC-1295 and Mod GRF 1-29. They tell your pituitary to release the growth hormone it has already produced and stored.
2. GHSR (Ghrelin Receptor): This is the target for ipamorelin and the older GHRPs (GHRP-2 and GHRP-6). They also signal the pituitary to release GH, but through a different pathway, while also amplifying the GHRH signal.

Hitting both pathways at once (the classic GHRH + GHRP combo) is meant to produce a larger pulse of growth hormone than either alone. In rat pituitary cells, the two amplified each other, but no controlled human trial of the Mod GRF 1-29 and ipamorelin combination has been published.

The human evidence on tolerance is thin. In one small study, 12 healthy older adults injected hexarelin (another GHRP) twice daily for 16 weeks. Their GH response fell by roughly 35-45% by weeks 4 and 16, a partial drop rather than a shutdown. Four weeks after stopping, a fresh dose produced a response no different from baseline.

Other data point the other way. In a two-year trial of MK-677, an oral ghrelin mimetic, daily use kept GH and IGF-1 at young-adult levels in 65 older adults. And in rat pituitary cells, the fading response to repeated GHRH looked more like depleted GH stores than receptor loss. So 'receptor burnout' is plausible, not proven. Users whose CJC/ipamorelin 'stopped working' may also have had an underdosed gray-market vial.

Practical Cycling Protocols for Fat Loss

The schedules below come from community guides and vendor material, not trials. Most pair a weekly micro-cycle with a longer macro-cycle, with the stated goal of giving the receptors time to 'reset' during the 'off' phase.

The Classic GHS Stack (CJC + Ipamorelin)

This is the stack users mention most often for leaning out while trying to keep muscle. CJC-1295 (specifically the 'no DAC' version, also known as Mod GRF 1-29) and ipamorelin are used together for their combined effect on GH pulses. As of October 2026, no trial has measured fat loss with either compound; our pages on CJC-1295 for fat loss and ipamorelin's human data cover what has been studied. Community guides describe the cycling strategy in two parts.

• The Micro-Cycle (Weekly): The schedule users report most often is 5 days on, 2 days off. The stated aim is to slow desensitization; no study has tested whether two days off does that. Many users simply take the weekend off.
• The Macro-Cycle (Monthly): Community guides typically describe 8 to 12 weeks on, followed by at least 4 weeks completely off. The 4-week break loosely matches the hexarelin study above, the only human data point behind it.

FDA's 2024 review found AOD-9604 failed to beat placebo in most human trials, all of them oral or IV. Our HGH Fragment 176-191 page covers how the two compounds differ.

The Exception to the Rule: GLP-1 Agonists

Semaglutide and tirzepatide are a different case. These are not growth hormone secretagogues; they are incretin mimetics, prescription medicines that primarily work by suppressing appetite and improving blood sugar control.

These peptides are not cycled in the traditional sense. Per their labels, treatment starts at a low weekly dose and steps up every four weeks to a maintenance dose, and the trials ran continuously for well over a year. In the STEP 1 trial, adults on semaglutide 2.4 mg weekly lost 14.9% of body weight over 68 weeks, against 2.4% on placebo.

The STEP 4 trial tested stopping. After 20 weeks on semaglutide, participants who switched to placebo regained 6.9% of body weight over 48 weeks, while those who stayed on lost another 7.9%. Appetite suppression is tied to the drug's presence in your system, so a break doesn't 'resensitize' anything.

Both are prescription medicines, and research-labeled vials sold online aren't an equivalent product; see the legal status of fat-loss peptides.

What 'Off' Actually Means

Community guides make a point that gets lost on a lot of people: switching from ipamorelin to GHRP-2 is not an 'off' cycle. It's like taking a break from squats by doing hack squats. You're still stimulating the exact same receptor system (the GHSR) with a slightly different tool.

A 1991 rat pituitary study supports that logic: cells that had stopped responding to GHRH still released GH when given GHRP-6, and the reverse, because the two use separate receptors.

A true off-cycle, as these guides use the term, means no GHRH analogs and no GHRPs: nothing that targets those pituitary receptors. How long full recovery takes after CJC-1295 with ipamorelin hasn't been measured.

What we still don't know

Users often describe cycling as periodization for the endocrine system, with the 'off' cycle as the deload. The analogy rests on assumptions nobody has tested for fat-loss stacks.

• No trial has compared continuous use with the 5-on/2-off or 8-12-weeks-on schedules for CJC-1295 with ipamorelin.
• The only human tolerance data for a GHRP (hexarelin) show a partial, reversible drop, while two years of MK-677 kept IGF-1 raised. Which pattern applies to ipamorelin is unknown.
• None of these stacks has trial data on fat loss itself, so a cycle that preserves the GH response may not mean more fat lost.

A common forum story is someone who gets results for 8 weeks, then chases them for another 6 months with no progress. Cycling might help, or the early results may have come from diet changes made at the same time. For the risks of using these compounds over years, see long-term effects of peptide use in bodybuilding.